Bristol Myers Squibb Acquires Mirati For $4.8 Billion

Bristol Myers Squibb, a US pharmaceutical corporation, announced a $4.8 billion deal to purchase cancer drugmaker Mirati Therapeutics. Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion," according to the...

EntroGen Secures US FDA Nod For CRCdx RAS Mutation Detection Kit

The US Food and Drug Administration (FDA) has approved EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a colorectal cancer targeted therapy. This historic premarket approval (PMA) represents a...

India, Taiwan Partner To Create Next Gen HealthTech

India and Taiwan have formed a new partnership to develop and promote breakthrough health-tech solutions. The International Trade Administration, Government of Taiwan, and the Commerce Development Research Institute (CDRI), as the Taiwan...

USFDA Nods Sun Pharma's NDA For Autoimmune Disease Treatment

Deuruxolitinib is an experimental medication for the treatment of moderate to severe alopecia areata, and Sun Pharmaceutical Industries Ltd. has reported that the United States Food and Drug Administration (USFDA) has approved its new drug...

Sai Life Sciences Chooses Dassault ONE Lab For Drug Discovery

Sai Life Sciences, the fastest-growing contract research, development, and manufacturing company in India, has chosen Dassault Systèmes' solutions to boost productivity, improve data quality, and promote collaboration in its research and...

Transcenta Bags US FDA Nod For Trial of Osemitamab

Transcenta Holding Limited, a clinical stage biopharmaceutical company, announces that the FDA has approved the TranStar 301 global phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line...

Emerging Technologies Shaping the Future of Drug Formulation

For many years, the discipline of drug formulation has been a pillar of the pharmaceutical business.

US FDA To Advance Novel Therapies For Stimulant Disorders

The US Food and Drug Administration (FDA) has released new draft recommendations to help sponsors develop therapies for stimulant use disorders. When it is completed, the guidance, Stimulant Use Disorders: Developing Drugs for Treatment, will be...

Sanofi, Teva Partner To Deliver Bowel Disease Treatment

Sanofi and Teva Pharmaceuticals, a US division of Teva Pharmaceutical Industries Ltd., announce a partnership to co-develop and co-commercialize TEV'574, an inflammatory bowel disease treatment drug currently undergoing phase 2b clinical trials...

Amber Implants Commenced clinical Trial with VCFix

Amber Implants, a cutting-edge medical technology firm producing next-generation spinal implants, has announced the formal commencement of clinical trials for the VCFix Spinal System. This first-in-human clinical trial will evaluate the safety and...

© 2025 India Pharma Outlook. All Rights Reserved.